Document is current
Any future updates will be listed below
-
Authors
Yang, Mingli
Nebozhyn, Michael V.
Schell, Michael J.
Gandhi, Nishant
Pflieger, Lance
Loboda, Andrey
Pledger, W. Jack
Soundararajan, Ramani
Maurin, Michelle
Wang, Heiman
Silva, Jetsen Rodriguez
Alden, Ashley
Coppola, Domenico
Elliott, Andrew
Sledge, George
Khushman, Moh’d
Lou, Emil
Goel, Sanjay
Yeatman, Timothy J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (UH3CA227955, R21CA256372 and R21CA255312.)
- License Information
-
More Information
Article History
Received: 17 September 2024
Accepted: 27 February 2025
First Online: 12 March 2025
Declarations
:
: 1. Merck-Moffitt CRCs: All the experiment protocol for involving human data was in accordance with the guidelines of national/international/institutional or Declaration of Helsinki. The tissue and clinical data were collected under the approval of the Institutional Review Board (IRB) of Moffitt Cancer Center with the informed written consent obtained from participating patients. The approved IRB No. is MCC14690.2. CARIS LS real-world CRC dataset: This study was conducted in accordance with the guidelines of the Declaration of Helsinki, Belmont Report, and U.S. Common Rule. Real-world clinical outcome information was obtained from insurance claims data. In keeping with 45 CFR 46.101(b) [], this study was performed using retrospective and de-identified clinical data. This study was thus consideredinstitutional review board (IRB) exempt, and no patient consent was necessary.
: Not applicable.
: The authors declare no competing interests.
